“It is fantastic news that our patent covering our solvent and tackifier free polyurea adhesive which is being exploited in our transdermal delivery of testosterone for women has been granted in the US,” commented Professor David Haddleton, Medherant founder, Chief Scientific Officer and co-inventor of this patent.

The claims of the granted patent cover drug delivery patches utilising Medherant’s silylated polyurea pressure sensitive adhesive. Medherant is utilising this technology for the development of the testosterone TEPI Patch that is in development for the treatment of hypoactive sexual desire disorder in post-menopausal women as well as a further product development collaboration with Bayer.

About Medherant

Medherant’s lead development product is a testosterone patch for post-menopausal women utilising Medherant’s novel transdermal TEPI Patch proprietary technology. Despite the recommendation contained in the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women there is no approved testosterone product for women.

In March 2024, Medherant announced that a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine.

The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton and is developing the novel transdermal TEPI Patch technology which can create patches that have more favourable wear characteristics for patients, with good adhesion and are non-irritant to patients whilst not leaving adhesive residue on patients’ skin.

In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.
TEPI Patch is a registered trademark of Medherant Limited.